Antidepressants primarily affect three neurotransmitters: serotonin, norepinephrine, and dopamine. These are the brain’s main mood-regulating chemical messengers, and different classes of antidepressants target them in different combinations and through different mechanisms. Newer treatments have expanded the list to include glutamate and GABA, opening up pathways that older medications never touched.
Serotonin: The Most Common Target
Serotonin is the neurotransmitter most frequently targeted by antidepressants. SSRIs (selective serotonin reuptake inhibitors) work by blocking the transporter protein that normally recycles serotonin back into the nerve cell after it’s been released. With that recycling process slowed down, serotonin lingers longer in the gap between neurons, amplifying its signal. This is the mechanism behind widely prescribed medications like fluoxetine, sertraline, and escitalopram.
Serotonin also has an indirect role in longer-term brain changes. It can stimulate production of a growth factor called BDNF, which supports the formation of new neural connections in areas like the hippocampus and prefrontal cortex. These structural changes, not just the chemical boost, are now believed to be a key part of how antidepressants actually relieve depression over time.
Norepinephrine: Energy, Focus, and Alertness
Norepinephrine plays a role in attention, motivation, and the body’s stress response. SNRIs (serotonin-norepinephrine reuptake inhibitors) block the reuptake of both serotonin and norepinephrine, though not equally. Venlafaxine has a 30-fold higher affinity for serotonin reuptake inhibition compared to norepinephrine. Duloxetine is about 10-fold more selective for serotonin. Both medications affect serotonin first and then begin inhibiting norepinephrine reuptake as the dose increases, which means side effects can shift over time as the norepinephrine effects kick in.
Not all SNRIs follow that pattern. Milnacipran is nearly balanced in its effects on both neurotransmitters and may even lean slightly more toward norepinephrine. Levomilnacipran is the only SNRI with roughly two-fold greater potency for norepinephrine over serotonin. These differences matter because they influence both effectiveness and side effects for individual patients.
Older tricyclic antidepressants (TCAs) also block reuptake of serotonin and norepinephrine, but they are far less selective. They bind to several other receptor types at the same time, including histamine receptors and acetylcholine receptors. That broad binding profile is why TCAs tend to cause more side effects like drowsiness, dry mouth, and blurred vision compared to newer options.
Dopamine: The Reward Signal
Dopamine is involved in motivation, pleasure, and reward. Most antidepressants don’t directly target it, with one notable exception. Bupropion inhibits the reuptake of both dopamine and norepinephrine, with slightly greater potency at the dopamine transporter. It has negligible effects on serotonin, even at high concentrations. That unique profile is why bupropion doesn’t cause the sexual dysfunction, weight gain, or sedation commonly associated with serotonin-targeting antidepressants. It remains the only widely available antidepressant that works primarily through the dopamine system.
How MAOIs Affect All Three at Once
Monoamine oxidase inhibitors take a completely different approach. Instead of blocking reuptake, they block the enzyme that breaks down serotonin, norepinephrine, and dopamine. Normally, monoamine oxidase clears these neurotransmitters after they’ve done their job. When the enzyme is inhibited, levels of all three neurotransmitters rise. This broad effect makes MAOIs powerful, but it also means they carry significant dietary and drug interaction risks, since the same enzyme breaks down certain compounds found in aged cheeses, cured meats, and other foods.
Mirtazapine: A Different Route to Serotonin and Norepinephrine
Mirtazapine doesn’t block reuptake at all. Instead, it blocks a specific type of receptor (called alpha-2 adrenergic receptors) that normally acts as a brake on neurotransmitter release. By disabling that brake, mirtazapine increases the release of both norepinephrine and serotonin. The norepinephrine boost happens through blockade of autoreceptors on norepinephrine neurons, while the serotonin boost is partly indirect, driven by norepinephrine activating serotonin-producing neurons. Mirtazapine also blocks certain histamine receptors, which is why it tends to cause sedation and appetite increase.
Glutamate: The Newest Target
Glutamate is the brain’s most abundant excitatory neurotransmitter, and it wasn’t part of the antidepressant conversation until recently. Esketamine, a nasal spray approved by the FDA in 2019 for treatment-resistant depression, works primarily by blocking a specific glutamate receptor called the NMDA receptor. This triggers a cascade of effects, including increased production of BDNF and activation of pathways that promote new synaptic connections. The result is a fundamentally faster-acting mechanism. Where traditional antidepressants take weeks, esketamine can begin reducing symptoms within hours to days.
GABA: Targeting Postpartum Depression
GABA is the brain’s main inhibitory neurotransmitter, calming neural activity rather than stimulating it. A newer class of antidepressants, neurosteroid GABA modulators, enhances the activity of GABA-A receptors. These medications were developed specifically for postpartum depression, where dramatic shifts in hormone-derived neurosteroids after childbirth appear to disrupt GABA signaling. Brexanolone (given as an infusion) and zuranolone (taken as a pill) both work through this mechanism, which is entirely distinct from the serotonin and norepinephrine pathways that traditional antidepressants use.
Why the Effects Take Weeks to Feel
One of the most counterintuitive things about antidepressants is the timing. SSRIs and SNRIs begin changing neurotransmitter levels within hours of the first dose, yet most people don’t feel meaningfully better for two to six weeks. This gap has pushed researchers to look beyond simple neurotransmitter levels for answers.
The current understanding is that the immediate chemical changes are just the first domino. What takes weeks is the downstream rewiring: activation of signaling pathways, changes in gene expression, and physical remodeling of synapses and dendrites in the hippocampus and prefrontal cortex. Depression is associated with reduced volume in these brain regions, and antidepressant treatment gradually promotes the growth of new neural connections through increased BDNF activity. These structural changes, rather than the initial bump in serotonin or norepinephrine, are what most closely tracks with symptom improvement.
When Serotonin Levels Get Too High
Because so many antidepressants increase serotonin, combining multiple serotonin-boosting medications or supplements creates the risk of serotonin syndrome, a potentially dangerous condition caused by excessive serotonin activity. Symptoms include muscle twitching or involuntary jerking, agitation, heavy sweating, rapid heartbeat, and in severe cases, dangerously high body temperature. Serotonin syndrome typically happens after starting a new serotonergic medication, increasing a dose, or combining drugs that each raise serotonin through different pathways. People on a stable dose of a single antidepressant who have been tolerating it well are unlikely to develop it spontaneously.